🕒 Created

Roivant Sciences shares rose 17.69% following positive Phase 2 clinical trial data for a new pulmonary hypertension treatment.

Roivant Sciences shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The data, presented at the European Respiratory Society International Congress 2026, showed that mosliciguat met its primary endpoint by achieving a statistically significant, placebo-adjusted pulmonary vascular resistance reduction of 56.3%.

Show the rest of this summary

This reduction was derived from a 51.3% drop in patients treated with mosliciguat compared to a 6.6% increase in the placebo group. thought:<channel|>{

Sources

Paywall and unreadable sources